What is the preferred immunization strategy for adults under 65 with immunocompromising conditions requiring both PCV13 and PPSV23?

The preferred immunization strategy for adults under 65 with immunocompromising conditions that require both the pneumococcal conjugate vaccine (PCV13) and the pneumococcal polysaccharide vaccine (PPSV23) is to administer PCV13 first, followed by PPSV23 at least 8 weeks later.

This sequence is recommended based on the immunogenicity and effectiveness of the vaccines. PCV13 helps to prime the immune system by providing a more robust immune response against the pneumococcal serotypes included in both vaccines. Following PCV13 with PPSV23 after at least 8 weeks ensures that the individual benefits from the protective effects of both types of vaccines without immunological interference.

Using this timing allows the body to mount a strong response to each vaccine, which is particularly critical for individuals with immunocompromising conditions, as they may have a diminished immune response. It's also important to note that this flip in the typical vaccination sequence helps maximize protection against pneumonia and other related infections that these individuals are at risk for.

The other strategies listed do not align with the current recommendations for the sequence of pneumococcal vaccination in this specific population, as they either delay the administration of PCV